Von Hippel-Lindau (VHL) antibody

Details for Product No. ABIN123801
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Synonyms BcDNA:RH61560, CG13221, DVhl, Dmel\\CG13221, Dvhl, VHL, d-VHL, d-vhl, dVHL, dmVHL, vhl, rca1, vhl1, hrca1, zgc:158722
(37), (1), (1)
(18), (17), (2), (1)
(4), (1), (1), (1), (1)
Western Blotting (WB)
(20), (15), (7), (2), (2), (2), (1)
Pubmed 9 references available
Quantity 50 μg
Shipping to United States ( )
Availability Will be delivered in 5 to 6 Business Days
Specificity Alpha-VHL reacts with the VHL protein in HeLa nuclear extract by Western blotting.
Alternative Name von Hippel-Lindau
Background Von Hippel-Lindau (VHL) disease is a hereditary cancer with a predilection for the central nervous system and retina. The von Hippel-Lindau tumor suppressor gene is mutated in families with von Hippel-Lindau disease and encodes a protein (VHL) of 213 amino acids with an acidic pentapeptide motif in the N-terminus. Mutations in the VHL gene result in constitutive expression of many hypoxi-induced genes, at least in part because of increases in the cellular level of hypoxia-inducible transcription factor HIF-1 alpha. VHL protein binds to elongin B, elongin C, and Cul2 to form a stable complex that targets hypoxia inducibal factors (HIFs) for degradation and transcriptional regulation. In addition, VHL protein has also been shown to interact with specific protein kinase C isoforms, histone deacetylases and HIF-1 inhibitor (FIH-1). alpha-VHL is an affinity-purified rabbit polyclonal antibody raised against the recombinant VHL protein.
Application Notes Recommended dilution range for Western blot analysis: 1:200 - 1:1000.
Restrictions For Research Use only
Format Liquid
Storage -80 °C
Background publications Mahon, Hirota, Semenza: "FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity." in: Genes & development, Vol. 15, Issue 20, pp. 2675-86, 2001 (PubMed).

Singh, Shields, Shields: "von Hippel-Lindau disease." in: Survey of ophthalmology, Vol. 46, Issue 2, pp. 117-42, 2001 (PubMed).

Kamura, Sato, Iwai et al.: "Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, Issue 19, pp. 10430-5, 2000 (PubMed).

Iwai, Yamanaka, Kamura et al.: "Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, Issue 22, pp. 12436-41, 1999 (PubMed).

Pal, Claffey, Dvorak et al.: "The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways." in: The Journal of biological chemistry, Vol. 272, Issue 44, pp. 27509-12, 1997 (PubMed).

Latif, Tory, Gnarra et al.: "Identification of the von Hippel-Lindau disease tumor suppressor gene." in: Science (New York, N.Y.), Vol. 260, Issue 5112, pp. 1317-20, 1993 (PubMed).

Linehan, Lerman, Zbar: "Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer." in: JAMA : the journal of the American Medical Association, Vol. 273, Issue 7, pp. 564-70, 1995 (PubMed).

Duan, Pause, Burgess et al.: "Inhibition of transcription elongation by the VHL tumor suppressor protein." in: Science (New York, N.Y.), Vol. 269, Issue 5229, pp. 1402-6, 1995 (PubMed).

Duan, Humphrey, Chen et al.: "Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 14, pp. 6459-63, 1995 (PubMed).

Catalog No. ABIN123801
Plus shipping costs $45.00

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)
Did you look for something else?